The free white paper from eyeforpharma includes input from Allergan, Takeda, Roche, Eisai, Ipsen and numerous other big names in the pharmaceutical industry. Get your copy here.
For Life Sciences companies, real-world evidence initiatives present a golden opportunity to demonstrate the clinical and economic value of their drugs and medical devices — and to get those products to market faster.
SCORR Marketing, in partnership with Applied Clinical Trials, conducted a survey with clinical trial professionals to learn how clinical trials have changed in the last 10 years and what we can expect as they continue to evolve in the future.
Pragmatic trials evaluate health technologies as they are used in actual medical practice, evaluating not only therapeutic benefit and risks in real-world populations, but also measuring economic impacts, and elucidating other important contributing factors such as prescribing practices and patient compliance.
Although real-world evidence (RWE) has become increasingly popular for its insight into the use and performance of marketed products (i.e., in the real world rather than in controlled clinical trials), many pharmaceutical companies struggle with the basic decision of which study design should be used to address a given research question. The lack of certainty is understandable; the “toolbox” of study types available to researchers is actually quite extensive, and there are pros and cons to each. In this paper, inVentiv Health experts present guidelines to help companies choose a study design that will ensure their Real-World Data (RWD) collection will be fit for their specific purpose.
Assessing treatment effectiveness of a time-varying drug regimen in longitudinal and observational outcomes research is difficult. This white paper provides a step-by-step illustration of the use of marginal structural models (MSMs) via an antiretroviral therapy (ART) case study.
NPC – Consumer Access to Specialty Medications.
Since 1990, the number of clinical trials performed in Russia has grown rapidly, from 292 in 2002 to 563 in 2007. Russia’s large population and centralized health care system are two aspects of its environment that make Russia so conducive to clinical trials. Pharm-Olam’s “Clinical Trials in Russia, The Promise and the Approach ” Whitepaper details how to tap into the potential the Russian market has to offer.
With well-defined barriers to physician access, the pharma industry is looking towards the pharmacist as a key stakeholder. To help define the interaction that pharma and the pharmacist could have, the latest eyeforpharma whitepaper outlines which companies are leading this new form of customer engagement. (Source: eyeforpharma, 2013).
The role, identity and connectivity of the payer is shifting in the face of global cost containment that is seeing all major pharma markets globally adopt new healthcare infrastructures geared around delivering economically efficient longer term positive outcomes. Clinicians and traditional payers combine within these emerging networks designed to assess cost-effectiveness at the national, regional and local level, presenting new engagement challenges and evidence requirements for the pharma industry.
Gain valuable insight into the EU5 and US country specific market trends; governmental regulation and formulary committee decision making processes; pricing and reimbursement regulations; why payers are vital to your research; helpful hints and recruitment considerations.
Download the white paper. Registration is required.